PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Boehringer Ingelheim Begins Clinical Development of First-In-Class ...
WEBMay 10, 2023 · INGELHEIM, Germany & SINGAPORE I May 09, 2023 I Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the ...
Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 …
WEBSep 7, 2022 · First Phase 2 Proof-of-Concept (POC) study demonstrating rapid clinical improvement and remission within days when Cryopyrin Associated Periodic Syndrome (CAPS) patients with flare ups were treated with ZYIL1, a …
Chengdu Origen and Vanotech Announce First Patient
WEBNov 21, 2023 · Clinical trial of KH631 evaluates single administration gene-therapy treatment for wet AMD. CHENGDU, China and ROCKAWAY, NJ, USA I November 20, 2023 I Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2201 multi-center Phase 1 clinical trial evaluating treatment with KH631 for patients with wet ...
Novo Nordisk acquires Embark Biotech, including its lead asset ...
WEBSep 1, 2023 · COPENHAGEN, Denmark I August 30, 2023 I Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat obesity and related co-morbidities.. Under the acquisition agreement for Embark Biotech, Novo Nordisk receives ...
Vaxxinity Announces First Subjects Dosed in Phase 1
WEBMar 21, 2023 · CAPE CANAVERAL, FL, USA I March 20, 2023 I Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a ...
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug …
WEBJan 9, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Amberstone Biosciences Secures $12 Million Series A Financing to ...
WEBJan 3, 2022 · LAGUNA HILLS, CA, USA I January 03, 2021 I Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round.The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital ...
CureVac Announces Solid Progress in Phase 2 COVID-19 and …
WEBNov 2, 2023 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
WEBJan 21, 2021 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.